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Summary
QUESTIONS UNDER STUDY: To evaluate pregnancy
outcome in pregnant women aged ≥45 years, termed very
advanced maternal age (VAMA).
METHODS: We retrospectively compared the outcome of
pregnancies in VAMA patients with controls aged 30 years
at time of delivery. Subgroups of singleton and multiple
pregnancies were also analysed. Incidences of maternal and
fetal adverse outcomes were measured. Statistical signific-
ance was set at p <0.05. Odds ratios (ORs) were adjusted
where necessary.
RESULTS: One hundred and twenty-seven VAMA preg-
nancies and 2066 control pregnancies of women aged 30
years were analysed. VAMA pregnancies had a higher rate
of maternal complications such as gestational hypertension
(3.9% vs 0.6%; OR 6.5), preeclampsia (14.2% vs 3.0%; OR
5.4, adjusted OR 4.4) and gestational diabetes (12.6% vs
3.6%; OR 3.8). Likewise, increased need for blood trans-
fusion (3.2% vs 0.7%; OR 4.8, adjusted OR 4.4) and pro-
longed hospitalisation >7 days (37.8% vs 15.1%; OR 3.42)
was found. Infant complications such as prematurity
(44.9% vs 16.2%; OR 4.2) and low birthweight <5th per-
centile (11.0% vs 5.6%; OR 2.1) were also increased.
CONCLUSION: Pregnant women of very advanced mater-
nal age (≥45 years) have significantly increased maternal
and fetal risks. Women postponing pregnancy or planning a
pregnancy in very advanced age should be informed about
these risks, in particular before artificial reproductive tech-
nologies are applied or “social freezing”.
Key words: very advanced maternal age, VAMA,
pregnancy outcome, multiple fetus pregnancy, maternal
age, social freezing
Introduction
In recent decades, a trend of shifted family planning to-
wards higher maternal age for socioeconomic and lifestyle
reasons could be observed in western countries [1]. At
the same time there were reasonable advances in artificial
reproductive technologies (ART) and these became more
and more easily accessible. Lately, some big companies
even began to offer egg freezing to their female employees
(social freezing) in order to keep them longer at work
without a baby break. These trends might lead to an in-
crease in pregnancies of women of perimenopausal age.
Social freezing may be the optimal strategy for companies
to employ young, cheap and powerful females and keep
them attached to the company in their most productive
phase. However, the propagated advantages of total gender
equality owing to biological independence may be at the
expense of these mothers and their children. Most import-
antly, the risk of stillbirth clearly increases with maternal
age [2–4]. In a Californian cohort, stillbirth was twice as
common in women 35 years of age or older as in those
younger than 35 years [2]. Women of very advanced mater-
nal age (VAMA) had a 2.4-fold risk increase for stillbirth
compared with women aged 20–24 years in a Canadian
study [3] and a 2.2-fold risk increase as compared to wo-
men aged 25–30 years in the US [4]. While there are some
data about increasing risks for adverse perinatal outcome
with increasing maternal age [5, 6], others show “generally
good” outcomes as well [7, 8]. Very advanced maternal age
is defined as maternal age of 45 years or older at the time of
delivery [7, 9]. Women of VAMA have a higher likelihood
for multiple pregnancies due to multiple ovarian follicu-
lar development after extensive follicle-stimulating hor-
mone (FSH) release as well as due to the use of ART [10],
which in itself leads to increased risks during pregnancy.
However, little is known concerning risks in singleton com-
pared with multiple pregnancies in VAMA women, with
separate controls. The objective of this study was, there-
fore, not only to evaluate perinatal risks in VAMA preg-
nancies as compared with 30-year-old controls in a single
tertiary centre, but also to stratify between the outcome of
singleton and multiple pregnancies.
Methods
A retrospective cohort study was conducted using data
from our electronic database Perinat 5.0. This database is
a local comprehensive electronic health record containing
all diagnoses and parameterised detailed clinical data about
the course of pregnancy, delivery, maternal, and infant out-
come.
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The study had ethical approval according to the Institution-
al Review Board decision for the use of anonymised pa-
tient data for medical research (13 April 2000 and 1 March
2012).
All deliveries in the University Hospital of Zürich between
January 1996 and December 2012 were analysed. A total of
36 328 deliveries fulfilled the inclusion criteria (≥24 weeks
of gestation or ≥500 g fetal weight).
Information on the following parameters was collected:
maternal age at delivery, parity, gestational age at delivery,
delivery mode, number of fetuses, occurrence of pregest-
ational diabetes mellitus, gestational diabetes mellitus,
chronic hypertension, gestational hypertension, preeclamp-
sia, HELLP syndrome (haemolysis, elevated liver en-
zymes, low platelet count), transfusion of blood products,
infant birthweight, obesity and duration of hospitalisation
after delivery.
The main study group consisted of all women with VAMA
(aged 45 years or older at time of delivery). This group
of women was compared with all women aged 30 years at
time of delivery during the same study period. Thirty-year-
old women were chosen as controls because the mean ma-
ternal age at delivery in Switzerland during the observed
period was 30.4 years [11].
Statistical methods
Statistical analysis was conducted using Sigmaplot 12.0
(Systat Software Inc., California, USA). The level of stat-
istical significance was set at p <0.05. Baseline character-
istics (age, parity, prior caesarean section, obesity (defined
as body mass index ≥30 kg/m2), chronic hypertension,
pregestational diabetes mellitus) were compared using the
chi-square test. Incidence of multiple fetus pregnancies,
hypertensive disorders (gestational hypertension, pree-
clampsia, eclampsia and HELLP syndrome), metabolic dis-
orders (gestational diabetes mellitus), transfusion of
packed red cells, prolonged hospital stay (>7 days) after de-
livery, placenta praevia, caesarean section, and infant out-
come (preterm birth <37/34/32 weeks of gestation, infant
birthweight <5th percentile) in both groups was compared
using the chi-square test. Unadjusted odds ratios (ORs)
with 95% confidence intervals (CIs) for the occurrence of
the above mentioned diagnoses in VAMA women as com-
pared with 30-year-old controls were calculated. A logistic
regression analysis was conducted with calculation of ad-
justed odds ratios for the incidence of preeclampsia (ad-
justed for chronic hypertension) and transfusion of blood
products (adjusted for prior caesarean section), as baseline
analysis revealed a statistically significant difference re-
garding chronic hypertension and prior caesarean section
between groups. In a subgroup analysis, singleton and mul-
tiple fetus pregnancies in VAMA and 30-year-old women
were compared separately for the most important dia-
gnoses.
Results
From 36 328 included deliveries, 127 VAMA women
(0.35%) and 2066 30-year-old women (5.69%) were iden-
tified. Mean maternal age was 47.0 (standard deviation 2.5)
and 30.0 (SD 0.4) years, respectively. In our study popula-
tion, a statistically significant difference for prior caesarean
section (9.5% vs 3.4%) and chronic hypertension (7.9% vs
0.7%) between VAMA and 30-year-old women (p <0.01
for each) was observed. No difference was observed for
parity, obesity and pre-existing diabetes mellitus (table 1).
In pregnancies of VAMA mothers, maternal morbidity was
significantly increased. Compared with 30-year-old wo-
men, the presence of gestational hypertension (3.9% vs
0.6%, OR 6.5 95% CI 2.3–18.5, p <0.001), preeclampsia
(14.2% vs 3.0%, OR 5.4 95% CI 3.1–9.5, p <0.001) and
gestational diabetes mellitus (12.6% vs 3.6%, OR 3.8 95%
CI 2.2-6.8, p <0.001) was significantly higher. Likewise,
the rate of caesarean section (76.4% vs 37.5%, OR 5.4
95% CI 3.5–8.2, p <0.001), transfusion of packed red cells
(3.2% vs 0.7%, OR 4.8 95% CI 1.6-14.7, p = 0.01) and
prolonged hospitalisation after delivery >7 days (37.8% vs
15.1%, OR 3.4 95% CI 2.3–5.0, p <0.001) was increased.
With respect to infants, VAMA pregnancies had a signi-
ficantly higher incidence of multiple pregnancy (28.4% vs
4.9%, OR 7.6 95% CI 4.9–11.8, p <0.001), preterm birth
(PTB) <37 weeks of gestation (44.9% vs 16.2%, OR 4.2
95% CI 2.9–6.1, p <0.001), PTB <34 weeks of gestation
(17.3% vs 8.6%, OR 2.2 95% CI 1.4–3.6, p <0.01), PTB
<32 weeks of gestation (11.8% vs 5.6%, OR 2.3 95% CI
1.3–4.0, p <0.01) and infant birthweight <5th percentile
(11.0% vs 5.6%, OR 2.1 95% CI 1.3–2.7, p = 0.02) as com-
pared with 30-year-old women (table 2, fig. 1). After ad-
justment of preeclampsia and maternal transfusion for rel-
evant factors, morbidity remained significant. Preeclamp-
sia was adjusted for chronic hypertension (adjusted OR 4.4
95% CI 2.4–8.0) and transfusion of packed red cells was
adjusted for prior caesarean section (adjusted OR 4.4 95%
CI 1.4–13.8).
In a subgroup analysis, singleton and multiple pregnancies
in VAMA and 30-year-old women were compared separ-
ately. In VAMA women, 91 singleton pregnancies and 36
multiple pregnancies were observed and compared with
1964 singleton and 102 multiple pregnancies in 30-year-
old women. For singleton pregnancies, the development of
preeclampsia (9.9% vs 2.4 %, OR 4.5, adjusted OR 8.6
95% CI 2.9–25.8, p <0.001), gestational diabetes mellitus
Figure 1
Incidence (%) of adverse maternal and infant outcome in very
advanced maternal age (VAMA) patients (black) and 30-year-old
patients (grey) within the overall group and within subgroups
(singleton and multiple-fetus pregnancies).
GDM = gestational diabetes mellitus; GHT =: gestational
hypertension; PTB = preterm birth; wk = weeks of gestation
** p<0.01, * p<0.05 (chi-square test)
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(8.8% vs 3.5%, OR 2.7 95% CI 1.2–5.7, p = 0.02) and pre-
term birth <37 weeks of gestation (26.4% vs 13.8%, OR
2.3 95% CI 1.4–3.7, p = 0.001) was found to be signific-
antly increased in VAMA pregnancies compared with those
of 30-year-old women (table 3, fig. 1).
In multiple pregnancies, VAMA women had a statistically
significant higher incidence of gestational diabetes mellitus
(22.2% vs 5.9%, OR 4.6 95% CI 1.5–14.3, p = 0.01), gest-
ational hypertension (11.1% vs 1.0%, OR 12.6 95% CI
1.4–117.1, p = 0.02), prolonged hospitalisation >7 days
after delivery (83.3% vs 40.2%, OR 7.4 95% CI 2.8–19.5,
p <0.001) and preterm birth <37 weeks of gestation (91.7%
vs 62.8%, OR 6.5 95% CI 1.9–22.8, p <0.01) (table 3,
fig. 1).
Discussion
Our data show statistically significant higher risks for preg-
nancies in women of very advanced maternal age (≥45
years) for maternal and infant morbidity. Thirty-year-old
women were selected as control group because the mean
age of women at the time of delivery was 30.4 years in
Switzerland during the observed period (1996–2012) [11].
As expected, there were significantly more multiple preg-
nancies in VAMA women than in 30-year-old women.
Even though we believe that this fact should not be seen
as a confounder but rather as a consequence of VAMA, as
these women have a higher likelihood for multiple preg-
nancies, we conducted a subgroup analysis of singleton
and multiple pregnancies separately to exclude this putat-
ive confounder. Our data reveal that not only in multiple
but also in singleton pregnancies increased risks for mater-
nal and infant morbidity are clearly present. Some paramet-
ers missed the level of statistical significance, possibly ow-
ing to smaller numbers in the subgroup analysis. Therefore,
multiple pregnancy is not the only cause for the increased
occurrence of adverse outcome in VAMA women.
Our data confirm the results of previous studies that de-
scribe higher rates of pregnancy and perinatal complica-
tions for VAMA women [5, 9, 12, 13]. However, although
Table 1: Study population.
30-year-old women
(n = 2066)
VAMA
(n = 127)
p-value OR (95% CI)
Age (mean (SD); in years) 30.0
(0.4)
47.0
(2.5)
Chronic hypertension 0.7%
(15)
7.9%
(10)
<0.001 11.69 (5.14–26.58)
Pregestational diabetes mellitus 0.6%
(12)
1.6%
(2)
0.43 2.74 (0.61–12.37)
Obesity (BMI ≥30 kg/m2) 6.0%
(123)
6.3%
(8)
0.97 1.06 (0.51–2.22)
Primiparity 50.4%
(1041)
43.3%
(55)
0.15
Prior caesarean section 3.4%
(70)
9.5%
(12)
0.001 2.98 (1.57–5.65)
BMI = body mass index; CI = confidence Interval; OR = odds ratio; SD = standard deviation; VAMA = very advanced maternal age (≥45 years)
Data are expressed as % (n) or as indicated; p-values are from the chi-square test; ORs in bold type are statistically significant
Table 2: Outcome of VAMA women in comparison with 30-year-old women.
30-year-old women
(n = 2066)
VAMA
(n = 127)
OR
(95% CI)
p-value Adjusted OR
(95% CI)
Gestational diabetes mellitus* 3.6% (75) 12.6% (16) 3.83 (2.16–6.78) <0.001
Gestational hypertension* 0.6% (13) 3.9% (5) 6.47 (2.27–18.45) <0.001
Preeclampsia* 3.0% (61) 14.2% (18) 5.43 (3.10–9.50) <0.001 4.41
(2.46–7.97)†
Maternal diagnoses
Eclampsia + HELLP 1.1% (22) 1.6% (2) 1.46 (0.34–6.29) 0.94
Twin pregnancy* 4.7% (98) 26.0% (33) 7.05 (4.52–11.01) <0.001
Triplet pregnancy* 0.2% (4) 2.4% (3) 12.47 (2.76–56.34) <0.001
Multiple pregnancy* 4.9% (102) 28.4% (36) 7.62 (4.93–11.76) <0.001
Placenta praevia 0.7% (15) 1.6% (2) 2.19 (0.50–9.67) 0.59
Caesarean section* 37.5% (775) 76.4% (97) 5.39 (3.54–8.19) <0.001
Transfusion of packed red cells* 0.7% (14) 3.2% (4) 4.77 (1.55–14.70) 0.01 4.41
(1.41–13.78)‡
Peripartum
diagnoses
Prolonged hospitalisation (>7 days)* 15.1% (312) 37.8% (48) 3.42 (2.34–4.99) <0.001
PTB <37 weeks* 16.2% (334) 44.9% (57) 4.22 (2.92–6.11) <0.001
PTB <34 weeks* 8.6% (178) 17.3% (22) 2.22 (1.37–3.61) <0.01
PTB <32 weeks* 5.6% (116) 11.8% (15) 2.25 (1.27–3.98) <0.01
Neonatal diagnoses
Birthweight <5th percentile* 5.6% (116) 11.0% (14) 2.08 (1.16–3.74) 0.02
CI = Confidence Interval; HELLP = Haemolysis, Elevated Liver enzymes, Low Platelet count; OR = Odds ratio; PTB = preterm birth; VAMA = very advanced maternal age
(≥45 years)
Data are expressed as % (n); p-values are from the chi-square test; ORs and adjusted ORs in bold type are statistically significant
* p <0.05
† adjusted for chronic hypertension
‡ adjusted for prior caesarean section
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an increased rate of multiple pregnancies was observed,
none of these studies analysed singleton and multiple preg-
nancies separately in detail. Interestingly, there are two
studies that report a generally good pregnancy outcome for
VAMA women [7, 8]. In both of these studies, the rate
of naturally conceiving VAMA women was relatively high
(96% [7] and 84% [8]). However, both studies lacked an
adequate control group and thus conclusions are difficult to
draw. Unfortunately, in our study we did not survey the rate
of women with previous use of ART. It might be interest-
ing to compare the outcome of VAMA women who con-
ceived naturally with VAMA women who became pregnant
through ART in a further study. The organism of naturally
conceiving VAMA women might be biologically younger
and thus more stable during the strain of pregnancy. As our
data did not include information about stillbirth, this im-
portant outcome variable could not be analysed.
A strength of our study is the relatively large number of
women included in a single centre study. Our electronic
database allows solid documentation of the requested in-
formation, which is filled in prospectively. Documentation
is completed for every woman before discharge and super-
vised by the attending consultant. Hence, the database al-
lows a reliable retrospective analysis. At the same time, as
in any single centre study, a possible selection bias can-
not be excluded as the experience of only one centre is
included in the analysis. A possible drawback is the di-
minished number of women with adverse outcome in the
subgroup analysis, above all in multiple pregnancies.
A clinically useful aspect of our study is the subgroup ana-
lysis, which allows a personalised risk assessment in preg-
nant VAMA women. Of our VAMA women, 28.4% had
multiple pregnancies, and thus it is important to know the
risks for singleton and multiple pregnancies on a separate
basis.
Furthermore, implications for the public healthcare system
should be considered, because with rising rates of VAMA
women these implications will gain increasing public and
political attention. We can show that VAMA is associated
with increased direct costs (prolonged hospital stay). In-
creased indirect costs (maternal complications, infant com-
plications due to prematurity) for the general public can be
assumed.
There is a tendency towards increasing maternal age in
western countries. Due to favourable advances in artificial
reproductive medicine and changes of socioeconomic and
lifestyle issues, very advanced maternal age is also likely
to increase. We believe that women who plan a pregnancy
at the age of 45 years or older should be informed about
the increased risks for metabolic, hypertensive, peripartum
and neonatal adverse outcome, especially before the use
of ART and even more when they choose to postpone a
wished pregnancy to a period of their life that is associated
with higher risks for themselves and their offspring. This
topic is even more relevant in times of company-paid egg-
freezing proposals.
Disclosure statement: No financial support and no other
potential conflict of interest relevant to this article was reported.
Authors contribution: C Haslinger: Protocol development,
Data collection, Data analysis, Manuscript writing, B Stoiber:
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Table 3: Subgroup analysis: singleton and multiple pregnancies.
30-year-old
patients
(n = 2066)
VAMA
(n = 127)
OR (95% CI) p-value Adjusted OR
(95% CI)
Single* 3.5% (69) 8.8% (8) 2.65 (1.23–5.69) 0.02Gestational diabetes mellitus
Multiple* 5.9% (6) 22.2% (8) 4.57 (1.46–14.28) 0.01
Single 0.6% (12) 1.1% (1) 1.81 (0.23–14.05) 0.92Gestational hypertension
Multiple* 1.0% (1) 11.1% (4) 12.63
(1.36–117.07)
0.02
Single* 2.4% (47) 9.9% (9) 4.48 (2.12–9.45) <0.001 8.58 (2.85–25.84)†Preeclampsia
Multiple 13.7% (14) 25% (8) 2.1 (0.82–5.37) 0.19 1.76 (0.64–4.83)†
Single 0.9% (18) 2.2% (2) 2.43 (0.56–10.63) 0.50
Maternal
diagnoses
Eclampsia + HELLP
Multiple 3.9% (4) 0% (0) 0.53
Single 0.6% (11) 2.2% (2) 3.99 (0.87–18.27) 0.21 3.36 (0.71–15.89)‡Transfusion of packed red
cells Multiple 2.9% (3) 5.6% (2) 1.94 (0.31–12.12) 0.84 1.98 (0.32–12.37)‡
Single 13.8% (271) 19.8% (18) 1.54 (0.91–2.62) 0.15
Peripartum
diagnoses
Prolonged hospitalisation
(>7d) Multiple* 40.2% (41) 83.3% (30) 7.44 (2.84–19.46) <0.001
Single* 13.8% (270) 26.4% (24) 2.25 (1.39–3.65) 0.001PTB <37 weeks
Multiple* 62.8% (64) 91.7% (33) 6.53 (1.88–22.76) 0.002
Single 7.4% (146) 12.1% (11) 1.71 (0.89–3.29) 0.15PTB <34 weeks
Multiple 31.4% (32) 30.6% (11) 0.96 (0.42–2.19) 0.91
Single 4.9% (96) 8.8% (8) 0.53 (0.25–1.13) 0.16PTB <32 weeks
Multiple 19.6% (20) 19.4% (7) 0.99 (0.38–2.58) 0.82
Single 5.7% (111) 9.9% (9) 1.83 (0.90–3.74) 0.15
Neonatal
diagnoses
Birth weight <5th percentile
Multiple 4.9% (5) 13.9% (5) 3.13 (0.85–11.53) 0.16
CI = confidence interval; HELLP = Haemolysis, Elevated Liver enzymes, Low Platelet count; OR = odds ratio; PTB = preterm birth; VAMA = very advanced maternal age
(≥45 years)
Data are expressed as % (n); p-values are from the chi-square test; ORs and adjusted ORs in bold type are statistically significant
* p <0.05
† adjusted for chronic hypertension
‡ adjusted for prior caesarean section
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Figures (large format)
Figure 1
Incidence (%) of adverse maternal and infant outcome in very advanced maternal age (VAMA) patients (black) and 30-year-old patients (grey)
within the overall group and within subgroups (singleton and multiple-fetus pregnancies).
GDM = gestational diabetes mellitus; GHT = gestational hypertension; PTB = preterm birth; wk = weeks of gestation
** p<0.01, * p<0.05 (chi-square test)
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